Psoriasis Not Tied to Myocardial Infarction in Patients With ESRD
TUESDAY, Nov. 1, 2022 (HealthDay News) -- Among individuals with end-stage renal disease (ESRD), psoriasis is not associated with an increased risk for myocardial infarction (MI), according to a study recently published in the American Journal of the Medical Sciences.
Naomi Siddiquee, from the Medical College of Georgia at Augusta University, and colleagues used the United States Renal Data System to identify 1.06 million patients with ESRD starting dialysis between 2004 and 2015.
The researchers report that in the whole cohort, 0.6 percent of individuals had psoriasis and 17.1 percent had MI. However, among the 6,823 patients with psoriasis, 24 percent developed an MI. In unadjusted models, psoriasis was associated with an increased risk for MI (odds ratio, 1.34; 95 percent confidence interval, 1.26 to 1.42), but when controlling for demographics, dialysis modality, access type, and comorbidities, psoriasis was not associated with MI (odds ratio, 0.95; 95 percent confidence interval, 0.89 to 1.01).
"Contrary to prior research in the general population, in the ESRD population, psoriasis was not associated with an increased risk of MI after controlling for various demographic and clinical parameters," the authors write. "These data emphasize the importance of an integrated approach since comorbidities may influence the choice of therapy for psoriasis and outcomes."
Abstract/Full Text (subscription or payment may be required)
Related Posts
ASN: Discontinuation of RAS Inhibitors Does Not Increase eGFR in CKD
WEDNESDAY, Nov. 9, 2022 (HealthDay News) -- For patients with advanced and...
European Man May Be 6th Person to Be ‘Cured’ of HIV
THURSDAY, July 20, 2023 (HealthDay News) -- It’s rare for someone with HIV to go...
Si sobreviviste a un infarto, la rehabilitación cardíaca te puede ayudar
JUEVES, 21 de septiembre de 2023 (HealthDay News) -- La rehabilitación cardíaca...
Extended-Release Morphine Does Not Reduce Breathlessness in COPD
WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- Daily low-dose extended release...